Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies - PubMed

5 hours ago

Depemokimab, an ultra-long-acting biologic targeting IL-5, allows twice-yearly dosing and showed a 46% reduction in the probability of first asthma exacerbation over 52 weeks compared to placebo.
Efficacy began by Week 4 and was sustained across both 26-week dosing periods, with significant reductions in annualized exacerbation rates, especially in patients with disease duration <10 years, comorbid CRSwNP, or on medium-dose ICS.
Improvements in patient-reported outcomes (SGRQ, ACQ-5, ANSD, ADSD scores) and rescue medication use were observed, particularly in those with baseline ACQ-5 scores ≥1.5, indicating enhanced asthma control and quality of life.
The pooled analysis from Phase III SWIFT-1/-2 trials highlights depemokimab's early and sustained efficacy in type 2 asthma, with benefits potentially greater in earlier disease stages before progression to high-dose ICS.

Hasty Briefsbeta